Causes of Death and Influencing Factors in Patients with Atrial Fibrillation

American Journal of Medicine

Volumn 129, Issue 12, 2016, Pages 1278-1287

  Fauchier, Laurent ^a   Villejoubert, Olivier ^a   Clementy, Nicolas ^a   Bernard, Anne ^a   Pierre, Bertrand ^a   Angoulvant, Denis ^a   Ivanes, Fabrice ^a   Babuty, Dominique ^a   Lip, Gregory Y H ^b,c  

^a SERVICE DE DERMATOLOGIE   (France)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

Atrial fibrillation; Death; Heart failure; Oral anticoagulation; Stroke

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ACUTE AORTIC SYNDROME; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HEART FAILURE WITH DECREASED EJECTION FRACTION; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFECTION; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; NEOPLASM; PRIORITY JOURNAL; SUDDEN CARDIAC DEATH; SYSTOLIC DYSFUNCTION; TRAUMATIC BRAIN INJURY; AGE DISTRIBUTION; CARDIOVASCULAR DISEASES; COMORBIDITY; EPIDEMIOLOGY; FRANCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX RATIO; STROKE;

ADMINISTRATION, ORAL; AGE DISTRIBUTION; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; FEMALE; FRANCE; HEART FAILURE; HUMANS; INFECTION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; STROKE;

EID: 84994171904     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2016.06.045     Document Type: Article

References (33)

1. 1 Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:12 (2007), 857–867.
2. 2 Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:9921 (2014), 955–962.
3. 3 Go, A.S., Hylek, E.M., Phillips, K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:18 (2001), 2370–2375.
4. 4 Guo, Y., Wang, H., Zhao, X., et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol 168:5 (2013), 4678–4684.
5. 5 Conen, D., Chae, C.U., Glynn, R.J., et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 305:20 (2011), 2080–2087.
6. 6 Piccini, J.P., Hammill, B.G., Sinner, M.F., et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes 5:1 (2012), 85–93.
7. 7 Benjamin, E.J., Wolf, P.A., D'Agostino, R.B., Silbershatz, H., Kannel, W.B., Levy, D., Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:10 (1998), 946–952.
8. 8 Gorin, L., Fauchier, L., Nonin, E., Charbonnier, B., Babuty, D., Lip, G.Y., Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest 140:4 (2011), 911–917.
9. 9 Camm, A.J., Lip, G.Y.H., De Caterina, R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:21 (2012), 2719–2747.
10. 10 Olesen, J.B., Torp-Pedersen, C., Hansen, M.L., Lip, G.Y.H., The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 107:6 (2012), 1172–1179.
11. 11 Pisters, R., Lane, D.A., Nieuwlaat, R., de Vos, C.B., Crijns, H.J., Lip, G.Y., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:5 (2010), 1093–1100.
12. 12 Apostolakis, S., Sullivan, R.M., Olshansky, B., Lip, G.Y.H., Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 144:5 (2013), 1555–1563.
13. 2 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 146:3 (2014), 719–726.
14. 14 Marijon, E., Le Heuzey, J.-Y., Connolly, S., et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 128:20 (2013), 2192–2201.
15. 15 Camm, A.J., Amarenco, P., Haas, S., et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 37:14 (2016), 1145–1153.
16. 16 Nieuwlaat, R., Eurlings, L.W., Cleland, J.G., et al. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 53:18 (2009), 1690–1698.
17. 17 Nielsen, P.B., Larsen, T.B., Gorst-Rasmussen, A., Skjøth, F., Lip, G.Y.H., β-Blockers in atrial fibrillation patients with or without heart failure: association with mortality in a nationwide cohort study. Circ Heart Fail, 9(2), 2016, e002597.
18. 18 Kotecha, D., Holmes, J., Krum, H., et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 384:9961 (2014), 2235–2243.
19. 19 Lip, G.Y.H., Laroche, C., Popescu, M.I., et al. Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. Eur J Heart Fail 17:6 (2015), 570–582.
20. 20 Go, A.S., Chertow, G.M., Fan, D., McCulloch, C.E., Hsu, C., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:13 (2004), 1296–1305.
21. 21 Coresh, J., Astor, B., Sarnak, M.J., Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 13:1 (2004), 73–81.
22. 22 Couser, W.G., Remuzzi, G., Mendis, S., Tonelli, M., The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 80:12 (2011), 1258–1270.
23. 23 McCullough, K., Sharma, P., Ali, T., et al. Measuring the population burden of chronic kidney disease: a systematic literature review of the estimated prevalence of impaired kidney function. Nephrol Dial Transplant 27:5 (2012), 1812–1821.
24. 24 Fauchier, L., Samson, A., Chaize, G., et al. Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. Open Heart, 2(1), 2015, e000290.
25. 25 Olesen, J.B., Lip, G.Y.H., Kamper, A.-L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:7 (2012), 625–635.
26. 26 Keating, R.J., Gersh, B.J., Hodge, D.O., et al. Effect of atrial fibrillation pattern on survival in a community-based cohort. Am J Cardiol 96:10 (2005), 1420–1424.
27. 27 Ahmed, A., Perry, G.J., Incident atrial fibrillation and mortality in older adults with heart failure. Eur J Heart Fail 7:7 (2005), 1118–1121.
28. 28 Taillandier, S., Brunet Bernard, A., Lallemand, B., et al. Prognosis in patients hospitalized with permanent and nonpermanent atrial fibrillation in heart failure. Am J Cardiol 113:7 (2014), 1189–1195.
29. 29 Testa, G., Cacciatore, F., Della-Morte, D., et al. Role of permanent atrial fibrillation (AF) on long-term mortality in community-dwelling elderly people with and without chronic heart failure (CHF). Arch Gerontol Geriatr 55:1 (2012), 91–95.
30. 30 Staszewski, J., Brodacki, B., Tomczykiewicz, K., Kotowicz, J., Stepien, A., Strokes in paroxysmal atrial fibrillation have more favorable outcome than in permanent atrial fibrillation. Acta Neurol Scand 119:5 (2009), 325–331.
31. 31 Wyse, D.G., Waldo, A.L., DiMarco, J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:23 (2002), 1825–1833.
32. 32 Writing Group Members, Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart Disease and Stroke Statistics–2016 update: a report from the American Heart Association. Circulation 133:4 (2016), e38–e60.
33. 33 Aouba, A., Eb, M., Rey, G., Pavillon, G., Jougla, E., Mortality data in France: the main causes of death in 2008 and trends since 2000. Bull Épidémiologique Hebd 22 (2011), 249–255.